22-Jun-2013 [ | E-mail | ] Contact: Pam Eisele 908-423-5042 Kim Hamilton 908-423-6831 908-391-0131 Carol Ferguson 908-423-4465 Merck WHITEHOUSE STATION, N.J., June 22, 2013 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc…
Source:New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
Saturday, June 22, 2013
New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment